- Business
- RYAH Group Inc. RYAH Group, Inc. (CSE: RYAH) operates as a technology company providing a personalized wellness ecosystem featuring IoT-connected medical devices, AI analytics, and big data analytics primarily for the medical cannabis and nutraceutical sectors; its core products include the RYAH Smart Inhaler, a volumetric airflow sensor-enabled device with mobile app integration for tracking and controlling inhalation doses of vaporized substances; the RYAH Smart Patch for on-demand transdermal delivery and monitoring of plant-based medicines and nutraceuticals; and the RYAH MD platform, enabling healthcare practitioners to remotely monitor, manage, and prescribe patient dosing regimens via HIPAA-compliant data aggregation and predictive analytics. The company targets clinics, physicians, dispensaries, pharmaceutical firms, and licensed processors seeking personalized treatment outcomes through strain-specific THC/CBD dosing correlated with patient demographics and session data, with geographic operations spanning the United States, Canada, New Zealand, and international markets. Founded in 2016 and headquartered in New York, New York, RYAH Group collects seed-to-consumer data via its IoT devices to support formulation efficacy analysis and telehealth solutions. Recent developments include a non-exclusive master distribution agreement with OMNI Medical Services LLC in 2021 for U.S. clinical trials marketing its products, alongside securing Health Canada medical device licensing for the Smart Inhaler system and New Zealand certification; however, the company faced significant challenges with a Failure-to-File Cease Trade Order issued by the Ontario Securities Commission in July 2022 due to delayed financial statements, culminating in a bankruptcy order for its Canadian subsidiary Groupe Ryah Inc. on July 23, 2024, under MNP Ltd. as trustee.